Look out Gilead, AbbVie’s hep C combo comes with stellar data, 8-week regimen and a killer price
The FDA handed AbbVie an OK and a helpful label on Thursday for its new combo therapy for hepatitis C. And now they’re rolling …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
